Unveiling Age-Related Phagocytic Differences and Immune Protection: The Pivotal Role of Mouse CD11b/c Antibodies by ANT BIO PTE. LTD.

1. Concept

Neonates exhibit unique susceptibility patterns to invasive infections—highly vulnerable to pathogens like Group B Streptococcus (GBS) yet remarkably resistant to others such as Streptococcus pneumoniae (Spn) compared to older individuals. This age-dependent protection is mediated by innate immunity, with neutrophils identified as the core effector cells. CD11b/c (part of the Mac-1/αMβ2 integrin complex) is a key receptor on phagocytes (neutrophils, monocytes/macrophages) that mediates pathogen recognition, adhesion, and phagocytosis via binding to opsonized molecules (e.g., complement fragments). Mouse CD11b/c antibodies are indispensable tools for investigating age-related differences in phagocytic function and the underlying immune protection mechanisms.

2. Research Frontiers

A key research frontier focuses on deciphering how age-related changes in efferocytosis (clearance of apoptotic cells) regulate CD11b/c-mediated phagocytosis. Neonatal phagocytes have lower efferocytosis activity, leaving CD11b more available for pathogen recognition—an innate advantage that declines with age. Researchers are exploring ways to modulate this pathway to enhance infection resistance in susceptible populations (e.g., the elderly, neonates with GBS).

Another active area of investigation involves expanding the understanding of CD11b/c’s role in age-specific pathogen susceptibility. Studies are exploring why CD11b-dependent protection works for Spn but not GBS, aiming to identify pathogen-specific interactions that could inform targeted therapies.

Preclinical research frontiers also include using CD11b/c antibodies to develop immune interventions—either enhancing CD11b function for infection prevention or blocking it to mitigate excessive inflammation in autoimmune diseases or sepsis.

3. Research Significance

Investigating CD11b/c and leveraging mouse CD11b/c antibodies holds profound significance for immunology research and clinical translation. In basic science, these antibodies enable the study of age-related innate immune adaptations, advancing our understanding of how phagocytic function evolves across the lifespan. This knowledge clarifies why neonates have unique infection risks and provides insights into age-related immune decline.

Clinically, the findings support the development of novel therapies: enhancing CD11b/c-mediated phagocytosis could improve infection outcomes in the elderly or immunocompromised, while targeted blocking may treat inflammatory disorders. Mouse CD11b/c antibodies accelerate preclinical development by validating mechanisms and evaluating therapeutic efficacy in animal models.

4. Related Mechanisms, Research Methods, and Product Applications

Related Mechanisms

Age-related differences in CD11b/c function stem from efferocytosis activity: neonatal phagocytes have low efferocytosis, preserving surface CD11b for pathogen binding and phagocytosis. As age increases, higher efferocytosis occupies CD11b, reducing its availability for infection clearance. As illustrated in the diagram, this correlates with age-dependent susceptibility: neonates outperform adults in clearing Spn and Streptococcus pyogenes (GAS) via CD11b-dependent mechanisms, but adults are more protected against GBS.

Research Methods and Product Applications

Mouse CD11b/c antibodies are versatile tools supporting diverse research applications. ANT BIO PTE. LTD.’s Mouse Anti-Rat CD11b/c Antibody (Catalog No.: S0B5014) stands out for its high specificity, affinity, and multi-platform compatibility, making it essential for studying age-related immune mechanisms.

Key Applications of the Antibody:

• Cell Identification and Phenotyping: The antibody labels CD11b/c-positive cells (neutrophils, monocytes/macrophages, microglia) in flow cytometry, enabling quantification and comparison of cell numbers, activation states, and CD11b expression levels across age groups.
• Functional Blockade Studies: In vivo or in vitro blockade of CD11b/c with the antibody validates its role in phagocytosis—e.g., abolishing neonatal mice’s Spn clearance advantage confirms CD11b as the core protective mechanism.
• Disease Model Analysis: In infection, neuroinflammation, or tumor models, the antibody monitors CD11b/c-positive cell recruitment and activation, evaluating age-related immune responses and therapeutic efficacy.
• Microglia Research: As a specific microglial marker, the antibody supports studies on age-related changes in neuroinflammation and neurodegenerative diseases.

Core Advantages of the Antibody:

• Exceptional Specificity: The antibody specifically recognizes CD11b/c on myeloid cells and microglia, with minimal cross-reactivity, ensuring accurate cell identification in complex tissues.
• Superior Detection Performance: It delivers bright, stable signals in flow cytometry and clear staining in immunohistochemistry, facilitating precise quantification and localization of target cells.
• Batch Consistency: Strict quality control ensures consistent potency and specificity across batches, guaranteeing reproducible results for long-term age-related studies.

Age-Related Pathogen Susceptibility and CD11b/C Dependency:

5. Brand Mission

ANT BIO PTE. LTD. is dedicated to advancing life science research and clinical diagnostics by providing high-performance, high-value core reagents and comprehensive solutions. Leveraging advanced development platforms—including recombinant rabbit monoclonal antibody, recombinant mouse monoclonal antibody, rapid mouse monoclonal antibody, and recombinant protein development platforms (E.coli, CHO, HEK293, Insect Cells), as well as the One-Step ELISA Platform and PTM Pan-Modification Antibody Platform—the company adheres to stringent quality standards and has successfully obtained EU 98/79/EC certification, ISO9001 certification, and ISO13485 certification. ANT BIO PTE. LTD. strives to support researchers worldwide in their pursuit of scientific breakthroughs in immunology, aging, and infectious diseases, driving innovations in diagnosis and treatment.

6. Related Product List

7. AI Disclaimer

This article is AI-compiled and interpreted based on the original work. All intellectual property (e.g., images, data) of the original publication shall belong to the journal and the research team. For any infringement, please contact us promptly and we will take immediate action.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.